A citation-based method for searching scientific literature

Björn Eliasson, Jan Ekelund, Rikard Amberntsson, Mervete Miftaraj, Ann-Marie Svensson. Diabetes Ther 2019
Times Cited: 2







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
189
100


Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
220
100

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
753
100

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
100

Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course.
Amy G Huebschmann, Rachel R Huxley, Wendy M Kohrt, Philip Zeitler, Judith G Regensteiner, Jane E B Reusch. Diabetologia 2019
30
100

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
539
100

Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting.
Wayne Weng, Ye Tian, Sheldon X Kong, Rahul Ganguly, Malene Hersloev, Jason Brett, Todd Hobbs. Clin Diabetes Endocrinol 2020
6
50

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
Aidin Rawshani, Araz Rawshani, Stefan Franzén, Björn Eliasson, Ann-Marie Svensson, Mervete Miftaraj, Darren K McGuire, Naveed Sattar, Annika Rosengren, Soffia Gudbjörnsdottir. N Engl J Med 2017
380
50

Cost analysis of type 2 diabetes mellitus treatment in economically developed countries.
Sara Ramzan, Peter Timmins, Syed Shahzad Hasan, Zaheer-Ud-Din Babar. Expert Rev Pharmacoecon Outcomes Res 2019
5
50

Excess risk of hospitalisation for heart failure among people with type 2 diabetes.
Annika Rosengren, Jon Edqvist, Araz Rawshani, Naveed Sattar, Stefan Franzén, Martin Adiels, Ann-Marie Svensson, Marcus Lind, Soffia Gudbjörnsdottir. Diabetologia 2018
13
50

Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data.
A Ringborg, M Martinell, J Stålhammar, D D Yin, P Lindgren. Int J Clin Pract 2008
39
50

Annual Medical Costs of Swedish Patients with Type 2 Diabetes Before and After Insulin Initiation.
Christin Bexelius, Johan Lundberg, Xuan Wang, Jenny Berg, Hans Hjelm. Diabetes Ther 2013
4
50

Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review.
Thomas R Einarson, Annabel Acs, Craig Ludwig, Ulrik H Panton. Value Health 2018
46
50

Burden of Illness in Type 2 Diabetes Mellitus.
Anthony Cannon, Yehuda Handelsman, Michael Heile, Michael Shannon. J Manag Care Spec Pharm 2018
27
50

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
Thwe Htay, Kyaw Soe, Arianna Lopez-Perez, Amy HoangAnh Doan, Michael A Romagosa, KoKo Aung. Curr Cardiol Rep 2019
7
50

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Aidin Rawshani, Araz Rawshani, Stefan Franzén, Naveed Sattar, Björn Eliasson, Ann-Marie Svensson, Björn Zethelius, Mervete Miftaraj, Darren K McGuire, Annika Rosengren,[...]. N Engl J Med 2018
310
50

Direct medical costs for patients with type 2 diabetes in Sweden.
F Henriksson, C D Agardh, C Berne, J Bolinder, F Lönnqvist, P Stenström, C G Ostenson, B Jönsson. J Intern Med 2000
85
50

Diabetes: the cost of illness in Sweden.
F Henriksson, B Jönsson. J Intern Med 1998
43
50


Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting.
Ugne Sabale, Johan Bodegård, Johan Sundström, Carl Johan Östgren, Peter Nilsson, Gunnar Johansson, Bodil Svennblad, Martin Henriksson. Prim Care Diabetes 2015
12
50

Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
Lars-Åke Levin, Lars Wallentin, Lars Bernfort, David Andersson, Robert F Storey, Gina Bergström, Carl-Johan Lamm, Magnus Janzon, Padma Kaul. Value Health 2013
18
50

Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study.
Frederik Persson, Johan Bodegard, Jorma T Lahtela, Thomas Nyström, Marit E Jørgensen, Majken Linneman Jensen, Hanne L Gulseth, Marcus Thuresson, Fabian Hoti, David Nathanson,[...]. Endocrinol Diabetes Metab 2018
12
50

Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.
Anna Norhammar, Johan Bodegard, Thomas Nyström, Marcus Thuresson, Klas Rikner, David Nathanson, Jan W Eriksson. Diabetes Obes Metab 2019
4
50

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
50

Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
Emily D Parker, Eric T Wittbrodt, Jeffrey T McPheeters, Juan P Frias. Diabetes Obes Metab 2019
3
50

Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study.
Lars Bernfort, Magnus Husberg, Ann-Britt Wiréhn, Ulf Rosenqvist, Staffan Gustavsson, Kristina Karlsdotter, Lars-Åke Levin. Diabetes Ther 2020
1
100

Estimating the marginal cost of a life year in Sweden's public healthcare sector.
Jonathan Siverskog, Martin Henriksson. Eur J Health Econ 2019
8
50



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.